BioCryst Pharmaceuticals, Inc. (BCRX) stock analysis
BCRX · BioCryst Pharmaceuticals, Inc.
Latest recorded price: USD 7.45
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
Fiscal 2017 figures: revenue growth 22.8%, free cash flow margin -164.7%, ROIC -43.5%. The model flags 2 risk signals for this company (2 high severity).